Duloxetine Hcl Capsule, Delayed Release
Product Images NDC 80425-0146

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine Hcl (NDC 80425-0146). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine HCl Dr 30mg Cap Qty 60 Ndc 80425 0146

Label for Duloxetine HCL DR 30 mg delayed-release capsules, 60 count, from Advanced Rx Pharmacy of Tennessee, LLC. The label includes the product name, strength, dosage form, quantity, NDC 80425-0146, lot number 60DUL30125, and expiration date 1/31/2025. It also shows store and use instructions with caution about federal law restrictions.*

FDA Label Image

Duloxetine HCl Dr 30mg Cap Qty 30 Ndc 80425 0146

The image shows a packaging label for Duloxetine HCL DR 30 mg capsules, delayed release, in a quantity of 30. The label identifies Advanced Rx Pharmacy of Tennessee, LLC as the labeler and displays the product NDC as 80425-0146. It includes lot number 30DUL30225 and expiration date 2/28/2025, with storage instructions to keep at room temperature 20°-25°C (68°-77°F). The label compares the product to Cymbalta and includes cautionary information about federal law prohibiting transfer of the drug.*

FDA Label Image

Image 10

A line chart comparing the percentage of patients improved based on percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily groups. The x-axis represents percent improvement from 0 to 100, while the y-axis shows the percentage of patients improved from 0% to 100%. Two descending trend lines are shown, with Duloxetine consistently having a higher percentage of patients improved compared to placebo at various pain improvement thresholds.*

FDA Label Image

Image 2

A line graph showing the proportion of patients with relapse over time from randomization to relapse in days. Two treatments are compared: Placebo (dashed line) and Duloxetine (solid line). The y-axis represents the proportion of patients with relapse from 0.0 to 1.0, and the x-axis represents time in days up to 250. The graph indicates that the proportion of patients with relapse is higher for Placebo compared to Duloxetine over the observed period.*

FDA Label Image

Image 6

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline, for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows the percentage of patients improved from 0 to 100%. The Duloxetine groups show higher improvement percentages compared to placebo across the range.*

FDA Label Image

Image 8

A line chart comparing the percentage of patients improved by placebo versus Duloxetine 60/120 mg once daily. The x-axis shows percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved. Two lines represent placebo and Duloxetine groups, displaying patient improvement across pain reduction thresholds.*

FDA Label Image

Image

Chemical structure of Duloxetine HCL, showing the molecular arrangement including the thiophene ring, naphthalene group, and amine with HCl component, as depicted in the image for Duloxetine HCL DR.*

FDA Label Image

Image3

A Kaplan-Meier curve graph showing the proportion of patients with relapse over time from randomization (days) comparing two treatments: placebo and duloxetine. The x-axis measures time in days up to 300, and the y-axis shows the proportion of patients with relapse from 0.0 to 1.0. The duloxetine curve shows a lower relapse proportion compared to placebo throughout the study period.*

FDA Label Image

Image4

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The graph compares the efficacy of these doses and placebo in pain improvement across a range from 0 to 100 percent.*

FDA Label Image

Image5

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing patient improvement rates decreasing as percent pain improvement thresholds increase.*

FDA Label Image

Image7

A line graph illustrating the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo, showing trends of patient improvement across different pain reduction thresholds.*

FDA Label Image

Image9

A line graph comparing the percentage of patients improved between placebo and Duloxetine 60 mg once daily based on percent improvement in pain from baseline (BOCF). The x-axis shows percent improvement categories from >0 to 100, and the y-axis displays the percentage of patients improved from 0 to 100%. Two lines represent placebo and Duloxetine groups, showing trends in patient improvement.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.